236 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional … of unknown liabilities, the risk of litigation and/or regulatory actions related to the proposed acquisition of Cerevel Therapeutics's business, risks related
8-K
ABBV
Abbvie Inc
3 Apr 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:06pm
Report on Form 8-K are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 … to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government
424B5
hfwirp6f
26 Feb 24
Prospectus supplement for primary offering
6:12am
424B5
pry3054o lck
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
4v0ubcenrjk4nkqqm
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
7af4khsdjutf8fn1ynw
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
EX-99.1
ls07eh3e6pjuogklavl
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
EX-99.1
5wd 1ko9ef
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
hthrikws3rmc
5 Jan 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:03pm
8-K
EX-99.1
n778opfnu
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
wxrpv7idw9
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
4hqqm 76x196ak2az
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
54ro68w
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
93p of0ep
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.2
trpj0
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am